Tumor extracellular vesicles loaded with exogenous Let-7i and miR-142 can modulate both immune response and tumor microenvironment to initiate a powerful anti-tumor response

Khani, Adeleh Taghi; Sharifzad, Farzaneh; Mardpour, Soura; Hassan, Zuhair Mohammad; Ebrahimi, Marzieh

doi:10.1016/j.canlet.2020.11.014

Cited by 27 publications

(15 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MiR-142 could function as either tumor suppressor or oncogene in a cell-specific manner. For example, miR-142 overexpression could regulate both immune response and tumor microenvironment to initiate a powerful anti-tumor response [ 13 ]. In contrast, miR-142 promoted organoid formation by breast cancer stem cells (BCSCs) and enhanced tumor growth initiated by human BCSCs in vivo [ 14 ].…”

Section: Discussionmentioning

confidence: 99%

Bevacizumab confers significant improvements in survival for ovarian cancer patients with low miR-25 expression and high miR-142 expression

Yue

et al. 2021

J Ovarian Res

View full text Add to dashboard Cite

Background Lymphovascular space invasion (LVSI) is the first step of hematogenous metastasis. Exploration of the differential miRNA expression profiles between LVSI-positive and LVSI-negative ovarian cancer tissues may help to identify key miRNAs involved in the hematogenous metastasis of ovarian cancer. This study is aimed to identify microRNAs (miRNAs) that are differentially expressed between LVSI-positive and LVSI-negative ovarian cancer tissues, followed by exploring their association with bevacizumab response in ovarian cancer patients. Methods The Cancer Genome Altas (TGGA) dataset was used to identify the differentially expressed miRNAs between LVSI-positive and LVSI-negative ovarian cancer tissues. The prognostic value of the differentially expressed miRNAs was determined using GSE140082 dataset. Results We showed that miR-25 and miR-142 were differentially expressed between LVSI-positive and LVSI-negative ovarian cancer tumors. Kaplan-Meier analysis indicated that high miR-25 expression was associated with increased progression free survival (PFS) and extended overall survival (OS). Moreover, patients with low miR-25 expression benefited significantly from bevacizumab treatment in terms of PFS. A similar trend was observed in terms of OS though without reaching statistical significance. In contrast, no significant survival benefits from bevacizumab were observed in patients with high miR-25 expression in terms of PFS and OS. There was no significant correlation between miR-142 expression and PFS. In contrast, high miR-142 expression was associated with reduced OS. Moreover, patients with high miR-142 expression benefited significantly from bevacizumab treatment in terms of PFS and OS. However, bevacizumab treatment conferred no significant improvements in both PFS and OS in patients with low miR-142 expression. The nomogram for PFS indicated that miR-25 expression had a larger contribution to PFS than debulking status and bevacizumab treatment. And the nomogram for OS illustrated both miR-25 expression and miR-142 expression as sharing a larger contribution to OS than bevacizumab treatment and debulking status. Conclusion In conclusion, miR-25 expression correlates with a better PFS and OS in ovarian cancer. Patients with low miR-25 expression and high miR-142 expression could benefit from bevacizumab treatment significantly.

show abstract

Section: Discussionmentioning

confidence: 99%

Bevacizumab confers significant improvements in survival for ovarian cancer patients with low miR-25 expression and high miR-142 expression

Yue

et al. 2021

J Ovarian Res

View full text Add to dashboard Cite

show abstract

“…This treatment substantially increased the strength of antitumor immunity, remodeled the TME of orthotopic HCC in mice with a deficiency in original immunogenicity, and delayed tumor growth (Zuo et al, 2020 ). In addition, some miRNAs, such as miR-142 and let-7i, also activate DCs and TLs, and tumor cell-derived EVs loaded with multiple miRNAs have been used to deliver tumor-specific antigens to DCs, significantly affecting the maturation of DCs and the activity of CTLs, reducing tumor volume and prolonging the survival of mice (Khani et al, 2021 ). This attempt to activate DCs using TEXs transporting antigens and exogenous substances has promoted the development of DC immunotherapy.…”

Section: Extracellular Vesiclesmentioning

confidence: 99%

Cell-derived biomimetic nanocarriers for targeted cancer therapy: cell membranes and extracellular vesicles

Zhao

et al. 2021

Drug Delivery

View full text Add to dashboard Cite

Nanotechnology provides synthetic carriers for cancer drug delivery that protect cargos from degradation, control drug release and increase local accumulation at tumors. However, these non-natural vehicles display poor tumor targeting and potential toxicity and are eliminated by the immune system. Recently, biomimetic nanocarriers have been widely developed based on the concept of 'mimicking nature.' Among them, cell-derived biomimetic vehicles have become the focus of bionics research because of their multiple natural functions, such as low immunogenicity, long circulation time and targeting ability. Cell membrane-coated carriers and extracellular vesicles are two widely used cell-based biomimetic materials. Here, this review summarizes the latest progress in the application of these two biomimetic carriers in targeted cancer therapy. Their properties and performance are compared, and their future challenges and development prospects are discussed.

show abstract

“…The miRNA content of the exosomes is also known to promote the progression of cancer (73), such as miRNA-15b (74) and miRNA-21 (75), while exosomal miRNA-22 (76), miRNA-142 (77), and miRNA-155 (31,78) have been shown to exert therapeutic effects against cancer. A study showed that after transfecting DNA vectors expressing miRNA-155 and miRNA-125b2 into pancreatic cancer cells, the altered CEVs had upregulated miRNA levels, as detected by the ExoQuick-TC exosome precipitation solution (31).…”

Section: Genetically Engineered Cancer Cells-derived Extracellular Vesiclesmentioning

confidence: 99%

Current Strategies for Cancer Cell-Derived Extracellular Vesicles for Cancer Therapy

Lin

Cai

2021

Front. Oncol.

View full text Add to dashboard Cite

Cancer cell-derived extracellular vesicles (CEVs), a novel type of therapeutic agent in cancer treatment, can be prepared from the autocrine secretion of various cancer cells, the direct extraction of cancer cells and the combination of cancer cell-derived membranes with advanced materials. With various bioactive molecules, exosomes are produced by cells for intercellular communication. Although cancer cell-derived exosomes are known to inhibit tumor apoptosis and promote the progression of cancer, researchers have developed various innovative strategies to prepare anti-tumor vesicles from cancer cells. With current strategies for anti-tumor vesicles, four different kinds of CEVs are classified including irradiated CEVs, advanced materials combined CEVs, chemotherapeutic drugs loaded CEVs and genetically engineered CEVs. In this way, CEVs can not only be the carriers for anti-tumor drugs to the target tumor area but also act as immune-active agents. Problems raised in the strategies mainly concerned with the preparation, efficacy and application. In this review, we classified and summarized the current strategies for utilizing the anti-tumor potential of CEVs. Additionally, the challenges and the prospects of this novel agent have been discussed.

show abstract

Tumor extracellular vesicles loaded with exogenous Let-7i and miR-142 can modulate both immune response and tumor microenvironment to initiate a powerful anti-tumor response

Cited by 27 publications

References 2 publications

Bevacizumab confers significant improvements in survival for ovarian cancer patients with low miR-25 expression and high miR-142 expression

Bevacizumab confers significant improvements in survival for ovarian cancer patients with low miR-25 expression and high miR-142 expression

Cell-derived biomimetic nanocarriers for targeted cancer therapy: cell membranes and extracellular vesicles

Current Strategies for Cancer Cell-Derived Extracellular Vesicles for Cancer Therapy

Contact Info

Product

Resources

About